Meridian Bioscience Inc. (VIVO) Monday said that US Food & Drug Administration has re-categorized its illumigeneGroup A Streptococcus and illumigene Group B Streptococcus tests as "Moderate Complexity" under the Clinical Laboratory Improvement Amendments.
Moderately complex tests are assays that are considered to be simple and easy to use. The categorization allows the benefits of the illumigene platform to be available to all Moderate Complexity laboratories that are in US hospitals and clinics, empowering them to offer an accurate, rapid, simple molecular test for each of these pathogens.
illumigene Group A Streptococcus is a qualitative molecular test for the detection of Group A Strep pharyngitis. Acute pharyngitis is one of the most frequent illnesses for which pediatricians and other primary care physicians are consulted.
Group B Streptococcus continues to be a major perinatal pathogen, for both mothers and their infants, and is associated with significant morbidity and mortality.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.